The Chemistry of Antihypertensive Agents

  • E. Schlittler

Abstract

In accordance with the wishes of the Editor, a chapter on the chemistry of antihypertensive agents precedes the pharmacological chapters. If the author has not succeeded in giving all chemical structures for antihypertensive agents mentioned in subsequent contributions, his only consolation for this failure is the fact that this “Handbuch” is concerned with activity of drugs and not with their chemistry. It is not the chemistry but the biological activity which counts in this field of research.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aldrich, P.E., Diassi, P.A., Dickel, D.F., Dylion, C.M., Hance, P.D., Huebner, C.F., Korzun, B., Kuehne, M.E., Liu, L.H., McPhillamy, H.B., Robb, E.W., Roychaudhuri, D.K., Schlittler, E., St. Andre, Van Tamelen, Weisenborn, F.L., Wenkert, E., Wintersteiner, O.: The stereochemistry of reserpine, deserpidine and related alkaloids. J. Amer. chem. Soc. 81, 2481–2494 (1959).Google Scholar
  2. Alles, G.A.: Comparative physiological action of some derivates of guanidine. J. Pharmacol. exp. Ther. 28, 251–276 (1926).Google Scholar
  3. Anderson, P. L., Houlihan, W.J., Manning, R.E.: Antihypertensive hydrazinopyridazines. Chem. Abstr. 73, 120, 655w (1971).Google Scholar
  4. Appel, W.: α-Isopropyl-α[(N-methyl-N-homoveratryl)γ-aminopropyl]-3, 4-dimethoxyphenyl-acetonitril, sein Nachweis im biologischen Material und sein Verhalten im Blut. Arzneimittel-Forsch. 12, 562–566 (1962).Google Scholar
  5. Arcari, G., Bernardi, L., Bosisio, G., Coda, S., Fregnan, G.B., Glässer, A.H.: 10-Methoxy-ergoline derivatives as α-adrenergic blocking agents. Experientia (Basel) 28, 819–820 (1972).PubMedGoogle Scholar
  6. Arcari, G., Dorigotti, L., Fregnan, G.B., Glässer, A.H.: Vasodilating and α-receptor blocking activity of a new ergoline derivative. Brit. J. Pharmacol. 34, 700P (1968).Google Scholar
  7. Archer, S., Wylie, D.W., Harris, L.S., Lewis, T.R., Schulenberg, J. W., Bell, M.R., Kullnig, R.K., Arnold, A.: l-(Indolalkyl)-4-arylpiperazines a new class of tranquilizers. J. Amer. chem. Soc. 84, 1306–1307 (1962).Google Scholar
  8. Archibald, J.L., Alps, B.J., J.F., Jackson, J. L.: Synthesis and hypotensive activity of benzamidopiperidyl ethylindole. J. med. Chem. 14, 1054–1059 (1971).PubMedGoogle Scholar
  9. Arya, V.P., Grewal, R.S., David, J., Kaul, C.L.: l-(5-Methyl-l-phenyl-4-pyrazolyl)-3-(4-((o-tolyl)piperazinyl)-l-propanone, a new synthetic antihypertensive agent. Experientia (Basel) 23, 514–515 (1967).PubMedGoogle Scholar
  10. Augstein, J., Green, S.M., Katritzky, Monro, A.M.: The synthesis, proof of structure, and biological activity of some monosubstituted aminoguanidines. J. med. Chem. 8, 395–397 (1965a).PubMedGoogle Scholar
  11. Augstein, J., Green, S.M., Monro, A.M., Potter, G.W.H., Worthing, C.R., Wrigley, T.I.: Adrenergic neurone blocking agents derived from 1, 4 benzodioxan. J. Med. Chem. 8, 446–456 (1965b); see also Monro, A.M.: A new synthesis of guanidines. Chem. Ind. (Lond.) 1964, 1806.Google Scholar
  12. Augstein, Monro, A.M., Potter, G.W.H., Scholfield, P.: Adrenergic neurone blocking agents III: Heterocyclic analogs of guanoxan. J. med. Chem. 11, 844–848 (1968).PubMedGoogle Scholar
  13. Ayers, J.B., Waggoner, W. H.: Synthesis and properties of a series of pentacyanoferrates. J. inorg. nuclear. Chem. 31, 2045–2051 (1969); Chem. Abstr. 71, 66.787j (1969).Google Scholar
  14. Ayman, D.: Potassium thiocyanate in the treatment of essential hypertension (its practicability). J. Amer. med. Ass. 96, 1852–1857 (1931).Google Scholar
  15. Ayman, D.: Bismuth subnitrate in the treatment of essential hypertension. J. Amer. med. Ass. 98, 545–548 (1932).Google Scholar
  16. Baines, M.W., Cobb, D.B., Eden, R.J., Fielden, R., Gardner, J.N., Roe, A.M., Tertiuk, W., Willey, G.L.: The synthesis and pharmacology of some stubstituted 1, 3 benzdioxoles and 1, 4-benzdioxans. J. med. Chem. 8, 81–90 (1965).PubMedGoogle Scholar
  17. Baker, P.D.: Sth. Med. Surg. 15, 579 (1859).Google Scholar
  18. Barger, G.: Ergot and Ergotism. London-Edinburgh: Gurney and Jackson 1931.Google Scholar
  19. Barger, G., Carr, F.H.: The alkaloids of ergot. J. chem. Soc. 91, 337–353 (1907).Google Scholar
  20. Barker, M.: The blood cyanates in the treatment of hypertension. J. Amer. med. Ass. 106, 762–767 (1936).Google Scholar
  21. Barlow, R.B., Ing, H.R.: Curare like action of polymethylene bis-quaternary ammonium salts. Nature (Lond.) 161, 718 (1948).PubMedGoogle Scholar
  22. Barlow, R.B., Ing, H.R.: Curare-like action of polymethylene bis-quaternary ammonium salts. Brit. J. Pharmacol. 3, 298–304 (1948).Google Scholar
  23. Barrett, W.E., Mull, R.P., Plummer, A.J.: Hypotensive activity of cis-cinnamyl guanidine sulfate. Experientia (Basel) 21, 506 (1965).PubMedGoogle Scholar
  24. Barron, D.I., Bavin, P.M.G., Durant, G.J., Natoff, I.L., Spickett, R.G., Vallance, D.K.: Potential antihypertensive agents: Some guanidine derivatives. J. med. Chem. 6, 705–711 (1963).PubMedGoogle Scholar
  25. Barron, D.I., Natoff, I.L., Vallance, D.K.: Pharmacology of N-[2-(2, 6-xylyloxy)ethyl]-guanidine sulfate: An adrenergic neurone blocking agent. Brit. J. Pharmacol. 25, 534–544 (1965).Google Scholar
  26. Barton, D.H.R., Jeger, O., Prelog, V., Woodward, R.B.: The constitution of cevine and some related alkaloids. Experientia (Basel) 10, 81–90 (1954).Google Scholar
  27. Baum, T., Shropshire, A.T., Rowles, G., Van Pelt, R., Fernandez, S.P., Eckfeld, D.K., Gluckman, M.I.: General pharmacologic actions of the antihypertensive agent 2, 6-dichlorobenzylidene aminoguanidine acetate, WY 8678. J. Pharmacol. exp. Ther. 171, 276–287 (1970).PubMedGoogle Scholar
  28. Begeka, A.D., Groisman, S.D.: Effect of different doses of sympatholytic isobarin on the evacuative function of the stomach in dogs: Fiziol. Zh. (Kiev) 21, 649–653 (1975). (Chem. Abstr. 83, 188405b (1975).Google Scholar
  29. Bell, M.R., Hoppe, J.O., Lape, H.E., Wood, D., Arnold, A., Selberis, W.H.: Antihypertensive activity of 7-azaindole-3-acetamidoxime and indole-1-acetamidoxime. Experientia (Basel) 23, 298–299 (1967).Google Scholar
  30. Bellasio, E., Carpi, C., Maffii, G., Testa, E.: 3-Hydrazino-6-aminopyridazines. Chem. Abstr. 75, 151.820s (1971).Google Scholar
  31. Bellasio, E., Parravicini, F., Testa, E.: 3-Hydrazinopyridazines containing basic groups in 6-position and possessing hypotensive activity. Farmaco, Ed. sci. 24, 919–929 (1969); Chem. Abstr. 72, 121.471z (1970).Google Scholar
  32. Bernardi, L.: Recent developments in the chemistry of ergot alkaloids. Chimica Industria 51, 563–569 (1969).Google Scholar
  33. Berthaux, P., Neuman, M.: Etude pharmacologique et clinique d’un nouvel hypotenseur réserpinique: DL 152 ou Biétaserpine. Arzneimittel-Forsch. 14, 1040–1045 (1964).Google Scholar
  34. Bhatia, B.B.: On the use of Rauwolfia serpentina in high blood pressure. J. Indian med. Ass. 11, 262–265 (1942).Google Scholar
  35. Bierbaum, B.A., Traverso, J. J., Whitehead, C.W.: Hypotensive 1, 2, 4-benzothiadiazines. J. med. Chem. 6, 272–275 (1963).PubMedGoogle Scholar
  36. Black, M.M., Zweifach, B.W., Speer, F.D.: Comparison of hypotensive action of sodium azide in normotensive and hypertensive patients. Proc. Soc. exp. Biol. (N. Y.) 85, 11–16 (1954).PubMedGoogle Scholar
  37. Bloomfield, D.K., Cangiano, J.L.: Guanadrel and guanethidine in hypertension. Clin. Pharmacol. Ther. 11, 200–204 (1970).PubMedGoogle Scholar
  38. Boehringer-Ingelheim: U.S. Pat. 3.190.802 (German prior. 10/9/1961). Chem. Abstr. 64, 2096 (1966).Google Scholar
  39. Botton, I., Kinnard, W.J., Buckley, J.P.: Hypotensive activity of β-heptyleneiminoethyl-amino guanidine sulfate. J. Pharmacol. exp. Ther. 152, 243–250 (1966).PubMedGoogle Scholar
  40. Boura, A. L. A., Copp, F. C., Green, A.F.: New adrenergic compounds. Nature (Lond.) 184, BA 70, (1959).PubMedGoogle Scholar
  41. Boura, A.L.A., Copp, F.C., Green, A.F.: Amidines as adrenergic neurone blocking agents. Nature (Lond.) 195, 1213–1214 (1962).PubMedGoogle Scholar
  42. Boura, A.L.A., Copp, F.C., Green, A.F., Hodson, H.F., Ruffel, G.K., Sim, M.F., Walton, E.: Adrenergic neurone blocking agents related to choline 2, 6-xylyl ether bromide (T.M.10), bretylium, and guanethidine. Nature (Lond.) 191, 1312–1313 (1961).PubMedGoogle Scholar
  43. Boura, A.L.A., Green, A.F.: The actions of bretylium: Adrenergic neurone blocking and other effects. Brit. J. Pharmacol. 14, 536–548 (1959).PubMedGoogle Scholar
  44. Bovet, D., Depierre, F., Be Lestrange, Y.: Propriétés curarisantes des éthers phénoliques à fonctions ammonium quaternaires. C. R. Acad. Sci. (Paris) 225, 74–76 (1947).Google Scholar
  45. Boyajy, L.D., Manning, R., McIntosh, R.E., Schäfer, F., Herzig, M., Schaaf, J., Trapold, J.H.: Cardiovascular effects of 2-(2, 6-dichlorophenyl)-5, 6-dihydroimidazo-(2, l-b-thiazole)-hydrobromide. 166th ACS Meeting, Chicago, August 1973, Abstracts Medi-22.Google Scholar
  46. Bream, J.B., Picard, C.W., White, T.G., Lauener, H.: Aralkylaminoguanidines and related compounds. J. med. Chem. 13, 1051–1057 (1970).PubMedGoogle Scholar
  47. Burn, J.H., Dale, H.H.: The action of certain quaternary ammonium bases. J. Pharmacol. exp. Ther. 6, 417–438 (1914).Google Scholar
  48. Buzas, A., Regnier, G.: Aminoalcoyl-1-réserpines. C.R. Acad. Sci. (Paris) 250, 1340–1342 (1960).Google Scholar
  49. Carstens, E.: Blutdrucksenkende Pharmaka. Pharmazie 27, 675–682 (1972).PubMedGoogle Scholar
  50. Cassinelli, C.M.: Therapeutic applications of the hypotensive action of Na-nitroprusside. Chem. Abstr. 52, 2283 (1958).Google Scholar
  51. Caujolle, F., Chanh, P.H., Lecointe, P.: Pharmacology of the nitrosopentocyano ferrate of cobalt. Arch. int. Pharmacodyn. 172, 487–495 (1968).PubMedGoogle Scholar
  52. Cavalleri, B., Bellasio, E., Sardi, A.: Synthesis of 6-trifluoromethyl-l, 4-dihydrazinophthalazine. J. med. Chem. 13, 148–149 (1970).PubMedGoogle Scholar
  53. Caviness, V.S., Umphlet, T.L., Peasley, E.D., Bell, T.A., Sattersfield, G.H.: Potassium rhodanide treatment of hypertension. N. C. med. J. 2, 283–288 (1941).Google Scholar
  54. Chopra, R.N., Chakravarti, M.: A preliminary note on the pharmacology of the alkaloids of R. serpentina. Indian J. Med. Res. 29, 763–768 (1941).Google Scholar
  55. Christensen, H.D., Haley, T.J.: Comparison of the effect of phentolamine and SU 12.080 on femoral blood flow in the anesthetized cat. Arch. int. Pharmacodyn. 164, 84–90 (1966).PubMedGoogle Scholar
  56. Chrusciel, M.: Chronic toxicity of carbethoxyphthalazino hydrazine and its influence on the excretion of 5-hydroxyindoleacetic acid and the activity of 5-HTP-decarboxylase in white rats. Brit. J. Pharmacol. 32, 104–112 (1968).PubMedGoogle Scholar
  57. Clerk, A., Paris, R., Sterne, J.: Action of octyl alcohol on the arterial pressure and surface tension of the blood of an animal. Compt. rend. soc. biol. 111, 774–776 (1932). Federal Register 37, No. 97, p. 10.015 (1972).Google Scholar
  58. Comer, W.T., Gomoll, A.W.: In: Burger, A. (Ed.): Medicinal Chemistry, p. 1046. (3rd Ed. New York-London-Sidney-Toronto: Wiley Interscience 1970.Google Scholar
  59. Cosnier, D., Duchene-Marullaz, P., Grimal, J., Rispat, G., Streichenberger, G.: Pharmacological properties of 2-(2-chloro-p-toluidino)-2-imidazolin enitrate (Tolonidine) I: Action on blood pressure and heart rate. Arzneimittel-Forsch. 25, 1557–1561 (1975a).Google Scholar
  60. Cosnier, D., Hache, J., Labrid, C., Streichenberger, G.: Pharmacological properties of 2-(2-chloro-p-toluidino)-2-imidazoline nitrate, III: Action on the secretions of the digestive tract and on the central nervous system, acute toxicity. Arzneimittel-Forsch. 25, 1926–1933 (1975c).Google Scholar
  61. Cosnier, D., Labrid, C., Rispat, G., Streichenberger, G.: Pharmacological properties of 2-(2-chloro-p-toluidino)-2-imidazoline nitrate (Tolonidine), a new antihypertensive agent, II: Action on cardiac contraction, circulatory parameters and diuresis. Arzneimittel-Forsch. 25, 1802–1806 (1975b).Google Scholar
  62. Cummings, J.R., Welter, A.N., Grace, J.L., Lipchuck, L.M.: Cardiovascular actions of guancydine in normotensive and hypertensive animals. J. Pharmacol. exp. Ther. 161, 88–97 (1968).PubMedGoogle Scholar
  63. Curwain, B.P., Fake, C.S., Gordon, J.L., Mehta, M.D., Miller, D., Poyser, R.H., Watts, E.A.: Synthesis and antihypertensive properties of some N-(guanidinoalkyl)pyrrolidines. J. med. Chem. 14, 737–742 (1971).PubMedGoogle Scholar
  64. Dannenfeldt, K.H.: Leonard Rauwolf (a biography), 321pp. Cambridge Mass.: Harvard University Press 1968.Google Scholar
  65. Delbarre, B., Schmitt, H.: Sedative effects of α-sympathomimetic drugs and their antagonism by adrenergic and cholinergic blocking drugs. Europ. J. Pharmacol. 13, 356–363 (1975).Google Scholar
  66. de Stevens, G., Wilhelm, M.: Antihypertensive agents. In: Jucker, E. (Ed.): Progress in Drug Research, Vol. 20, pp. 197–259. Basel-Stuttgart: Birkhäuser 1976.Google Scholar
  67. Doebel, K.J., Francis, J.E.: 1, 2, 8, 9-Tetraazaphenalenes. Chem. Abstr. 70, 106.567a (1969).Google Scholar
  68. Druey, J.: Pyridazines in the synthesis of drugs. Angew. Chem. 70, 5–13 (1958).Google Scholar
  69. Druey, J., Marxer, A.: Hypotensive hydrazinophthalazines and related compounds. J. med. Chem. 1, 1–21 (1959).Google Scholar
  70. Druey, J., Ringier, B.H.: Hydrazine derivatives of phthalazines and pyridazines. Helv. chim. Acta 34, 195–210 (1951).Google Scholar
  71. Druey, J., Tripod, J.: Hydralazines. In: SchLIttler, E. (Ed.): Antihypertensive Agents, pp. 223–262. New York-London: Academic Press 1967.Google Scholar
  72. Duchesne, E.A.: Répertoire des plantes utiles et des plantes vénéneuses du globe, p. 35. Paris 1836.Google Scholar
  73. Ehrhart, G., Ruschig, H.: Arzneimittel, 2.te Aufl., Vol. 2, p. 150, 1972. Weinheim, Germany: Verlag ChemieGoogle Scholar
  74. Ehrreich, S.J., Heringslake, J.E., Warren, F.R., Weinstock, J., Tedeschi, R.E.: Pharmacological effects of an unusual hypotensive agent (SKF 11.197). Effects on the cardiovascular system. Arch. int. Pharmacodyn. 179, 284–302 (1969).PubMedGoogle Scholar
  75. Ernest, I., Jilek, J.O., Vejdelek,Z.J., Protiva, M.: Über einige neue (-)-Methylreserpatester. Coll. Czech. Chem. Commun. 24, 266–273 (1964).Google Scholar
  76. Ernest, J., Protiva, M.: (±)Methyl-O-(O-carbethoxysyringoyl)-10-methoxydeserpidate. Coll. Czech. Chem. Commun. 26, 1137–1144 (1961).Google Scholar
  77. Ernest, I., Protiva, M.: Synthese des racem. 12-Methylmercaptodeserpidins. Coll. Czech. Chem. Commun. 28, 3106–3112 (1963).Google Scholar
  78. Everett,A.J., Lowe, L.A., Wilkinson, S.: Revision of the structures of (+)-tubocurarine chloride and (+)-chondrocurine. Chem. Commun. 1970, 1020–1021.Google Scholar
  79. Fielden, R., Green, A.L.: A comparative study of the noradrenaline-depleting and sympathetic blocking actions of guanethidine and (-)-β-hydroxyphenethylguanidine. Brit. J. Pharmacol. 30, 155–165 (1967).PubMedGoogle Scholar
  80. Fielden, R., Green, A.L.: Optical isomers of β-hydroxyphenethylguanidine: Effects on heart noradrenaline and sympathetic blockade. Brit. J. Pharmacol. 32, 350–359 (1968).PubMedGoogle Scholar
  81. Fielden, R., Green, A.L., Willey, G.L.: Adrenergic neurone blocking activity of some aralkylguanidines. Brit. J. Pharmacol. 24, 395–407 (1965).PubMedGoogle Scholar
  82. Fourneau, E., Bovet, D.: Recherches sur l’action sympatholytique d’un nouveau dérivé du dioxane. Arch. int. Pharmacodyn. 46, 178–191 (1933a).Google Scholar
  83. Fourneau, E., Bovet, D.: Sympatholytic action of a new derivative of dioxan. Compt. rend. soc. biol. 113, 388–390 (1933b).Google Scholar
  84. Fourneau, E., Maderni, P., De Lestrange, Y.: Heterocyclic bases derived from coumarans and benzodioxan. J. Pharmacol. Chim. 18, 185–191 (1933).Google Scholar
  85. Freis, E.D.: Hypertension: A controllable disease. Clin. Pharmacol. Ther. 13, 627–632 (1972).PubMedGoogle Scholar
  86. Freyburger, W.A., Weeks, J.R., Ducharme, D.W.: Cardiovascular actions of the hypotensive agent N, N-diallylmelamine (U 7720) Arch. exp. Path. Pharm. 251, 39–47 (1965).Google Scholar
  87. Gadekar, S.M., Nibi, S., Cohen, E.: Hypotensive activity of some cyanoguanidines. J. med. Chem. 11, 811–814 (1968).PubMedGoogle Scholar
  88. Gifford, R.W.: Hypotensive Drugs. In: Modell, W. (Ed.): Drugs of Choice 1970–1971. St. Louis, Mo.: C. V. Mosby.Google Scholar
  89. Giudicelli, R., Beauvallet, M., Chabrier, P., Najer, H.: Sur l’action vasculaire de quelques amino-2-oxazolines. C. R. Acad. Sci. (Paris) 247, 891, 2494–2497 (1959).Google Scholar
  90. GiudicellI, R., Najer, H., Lefèvre, F.: Relations between structure and activity in the N-(β-guanidinoethyl)azaspiroalkane series. C. R. Acad. Sci. (Paris) 260, 2944–2947 (1965).Google Scholar
  91. Giudicelli, R., Najer, H., Sarret, M., Prouteau, M.: The pharmacologic activity in the N(β-guanidinoethyl)azaspiroalkane series. C. R. Acad. Sci. (Paris) 259, 1596–1598 (1964).Google Scholar
  92. Giudicelli, R., Schmitt, H.: Propriétés antihypertensives et mécanisme d’action de la (diméthyl-2, 6-phenylamino)-2-oxazoline-1, 3. J. Pharmacol. 1, 339–358 (1970).Google Scholar
  93. Goldring, W., Chasis, H.: Thiocyanate therapy in hypertension I: Observations on its tyxic effects. Arch, intern. Med. 49, 321–329 (1932).Google Scholar
  94. Graubner, W., Wolf, M.: Kritische Betrachtungen zum Wirkungsmechanismus des 2-(2, 6-dichlorophenylamino)-2-imidazolinhydrochlorids. Arzneimittel-Forsch. 16, 1055–1058 (1966).Google Scholar
  95. Greshoff, M.: Übersicht der alkaloidhaltigen Apocynaceen in Niederländ. Indien. Chem. Ber. 23, 3543 (1890).Google Scholar
  96. Groot, S. de , Strating, J.: Reserpine analogs I. Rec. Trav. chim. Pays-Bas 80, 121–133 (1961).Google Scholar
  97. Gross, F., Druey, J., Meier, R.: A new group of antihypertensive substances with a special mode of action. Experientia (Basel) 6, 19–21 (1950).Google Scholar
  98. Gupta, J.C., Ghosh, S., Dutta, A.T., Kahali, B.S.: A note on the hypnotic principle of R. serpentina. J. Amer. pharm. Ass. 36, 416 (1947).PubMedGoogle Scholar
  99. Gupta, J.C., Kahali, B.S., Dutt, A.: The hypnotic effect of a resin fraction isolated from the root of R. serpentina Benth., obtained from Dehra-Dun. Indian J. med. Res. 32, 183–188 (1944).Google Scholar
  100. Gutman, J.: Modern Drug Encyclopedia and Therapeutic Guide, 1941, 138–139.Google Scholar
  101. Hammer, J., Ulrych, M., Freis, E.: Hemodynamic and therapeutic effects of guancydine in hypertension. Clin. Pharmacol. Ther. 12, 78–90 (1971).PubMedGoogle Scholar
  102. Hansson, L., Pascual, A., Julius, S.: Comparison of guanadrel and guanethidine. Clin. Pharmacol. Ther. 14, 204–208 (1973).PubMedGoogle Scholar
  103. Hartmann, M., Isler, H.: Chemische Konstitution und pharmakologische Wirksamkeit von in 2-Stellung substituierten Imidazolinen. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 192, 141–154 (1939).Google Scholar
  104. Heise, A., Kroneberg, G., Schlossmann, K.: α-Sympathomimetische Eigenschaften als Ursache der blutdrucksteigernden und blutdrucksenkenden Wirkung von BAY 1470 (2-(2-, 6-xylidino)-5, 6-dihydro-4H-1,3-thiazinhydrochlorid). Naunyn-Schmiedebergs Axch. Pharmak. 268, 348–360 (1971).Google Scholar
  105. Helgen, L., Stoutland, O., Agre, C.L.: Pyrolysis of N-phenylthiocarbamyl ethylenediamine and related materials. J. Org. Chem. 24, 884–886 (1959).Google Scholar
  106. HermannHermann: Arch. f. Physiol. 39, 419 (1886); Thesis, Univ. Königsberg 1887, p. 34.Google Scholar
  107. Hershenson, F.M., Rozek,L.F.: Synthesis and antihypertensive activity of 2-arylamino-l-azacycloalkenes. J. med. Chem. 14, 907–909 (1971).PubMedGoogle Scholar
  108. Hess, H.J., Cronin, T.H., Scriabine, A.: Antihypertensive 2-Amino-4(3H)-quinazolinones. J. med. Chem. 11, 130–136 (1968).PubMedGoogle Scholar
  109. Hidaka, H., Hara, F., Hashizume, V., Yano, M.: Selective inhibition of dopamine β-hydroxylase in the peripheral tissues by 5-dimethyldithio-carbamylpicolinic acid, its effect on stress-induced ulcer, ethanol-induced sleep and blood pressure. J. Pharmacol. exp. Ther. 191, 384–392 (1974).PubMedGoogle Scholar
  110. Hidaka, H., Nagatsu, T., Takeya, K., Takeuchi, T., Suda, H., Kojiri, K., Matsuzaki, M., Umezawa, H.: Fusaric acid, a new hypotensive agent produced by fungi. J. Antibiot. (Tokyo) 22, 228–230 (1969); Chem. Abstr. 71, 29.127y (1969).PubMedGoogle Scholar
  111. Hidaka, H., Takeya, K.: Blood pressure decreased by halobutylpicolinic acid, an inhibitory of dopamine β-hydroxylase Nature (Lond.) 239, 334–335 (1972).Google Scholar
  112. Hieber, W., Nast, R., Proeschel, E.: Inorganic compounds of nitric oxide VI: The nitrosylcyano nickel complex. Z. anorg. Chem. 256, 145–158 (1948).Google Scholar
  113. Hill, H.E.: A contribution to the toxicity of sodium nitroprusside, the decomposition and determination of sodium nitroprusside. Aust. J. chem. Inst. 9, 82–93 (1942).Google Scholar
  114. Hoefke, W., Kobinger, W., Walland, A.: Relationship between activity and structure in the derivatives of Clonidine: Arzneimittel-Forsch. 25, 786–793 (1975).Google Scholar
  115. Hoffmeister, W., Krueck, F.: Mechanism of action of potassium rhodanide as explanation for the blood pressure lowering effect in hypertension. Klin. Wschr. 32, 106–110 (1954).PubMedGoogle Scholar
  116. Hofmann, A.: Die Mutterkornalkaloide. Encke, Stuttgart 1964.Google Scholar
  117. Houlihan, W. J., Manning, R.E.: Secondary aminopyridazines as central nervous stimulants and as antihypertensives. Chem. Abstr. 75, 49.118g (1971).Google Scholar
  118. Houlihan, W.J., Manning, R. E.: Pharmacologically active tertiary aminopyridazine derivatives. Chem. Abstr. 77, 152.207a (1972).Google Scholar
  119. Huebner, C.F.: Rauwolfia Alkaloids XIII: Derivatives of reserpine. J. Amer. chem. Soc. 76, 5792 (1954).Google Scholar
  120. Hueni, A.: Verfahren zur Herstellung eines neuen Imidazolins. A.P. 2.868.802. Chem. Abstr. 53, 10.253 (1959).Google Scholar
  121. Ishii, Y., Fujii, Y., Mimura, C., Umezawa, H.: Pharmacological action of FD-008, a new dopamine β-hydroxylase inhibitor. Arzneimittel-Forsch. 25, 55–59 (1975).Google Scholar
  122. Ishii, Y., Homma, M., Yoshikawa, A., Umezawa, H.: Pharmacological action of FD-008, a new dopamine -hydroxylase inhibitor. Arzneimittel-Forsch. 25, 181–185 (1975); see also Ishii, Y., Fujii, Y., Umezawa, H.: Jap. J. Pharmacol. 23, Suppl., 53, Abstr. 76 (1973).Google Scholar
  123. Itallie, L. van, Steenhauer, A.J.: R. serpentina Benth. Arch. Pharm. 270, 313–322 (1932).Google Scholar
  124. Jeger, O., Prelog, V.: Steroid alkaloids: Veratrum group. In: Manske, R.H.F. (Ed.): The Alkaloids, Vol. VII, pp. 363–417. New York-London: Academic Press 1960.Google Scholar
  125. Jirkovsky, I., Protiva, M.: Synthese des racem. 10, 11-ethylendioxydespyrrolodeserpidins. Coll. Czech. Chem. Commun. 28, 2577–2581 (1962).Google Scholar
  126. Johnson, C.C.: The actions and toxicity of sodium nitroprusside. Arch. int. Pharmacodyn. 35, 480–496 (1929).Google Scholar
  127. Jones, P.H., Somani, P., Antihypertensive. U.S. Pat. 3840663 (3/23/1973 and 10/8/1974).Google Scholar
  128. Jung, F., Petsch, G.: On the hypotensive activity of pentacyano ferrates, especially sodium nitroprusside. Acta biol. med. Germ. 19, 781–783 (1967).PubMedGoogle Scholar
  129. Kahn, M.M., Ahmad, N.: Nitroprusside complexes of divalent cobalt, nickel, cadmium, zinc, copper, mangan, iron and trivalent titanium. Z. Anorgan. Allgem. Chem. 354, 301–306 (1967). Chem. Abstr. 68, 16598 (1968).Google Scholar
  130. Keeler, R. F.: Teratogenic compounds of V. californicum VII: The structure of the glycosidic alkaloid cycloposine. Steroids 13, 579–588 (1969).PubMedGoogle Scholar
  131. Keeler, R.F.: Teratogenic compounds of V. californicum XI: Gestational chronology and compound specifity in rabbits. Proc. Soc. exp. Biol. (N. Y.) 136, 1174–1179 (1971a).PubMedGoogle Scholar
  132. Keeler, R.F.: Teratogenic compounds of V. californicum XIII: Structure of muldamine. Steroids 18, 741–752 (1971b).PubMedGoogle Scholar
  133. Keeler, R.F.: Teratogenic compounds of V. californicum XIV: Limb deformations produced by cyclopamine. Proc. Soc. exp. Biol. (N. Y.) 142, 1287–1291 (1973).PubMedGoogle Scholar
  134. Keeler, R.F., Binns, W.: Possible teratogenic effects of veratramine. Proc. Soc. exp. Biol. (N. Y.) 123, 921–923 (1966).PubMedGoogle Scholar
  135. Keeler, R.F., Binns, W.: Teratogenic compounds from V. californicum III: Malformations of veratramine-induced type from ingestio nof plant or roots. Proc. Soc. exp. Biol. (N. Y.) 126, 452–454 (1967).Google Scholar
  136. Kersting, F.: Klinische Prüfung, Phase I: Arzneimittel-Forsch. 23, 1657–1659 (1973).Google Scholar
  137. King, H., Lourie, E. M., Yorke, W.: New trypanocidal substances. Lancet 1937 II, 1360–1363.Google Scholar
  138. Korduba, C.A., Veals, J., Wohl, A., Symchowicz, S., Tabachnick, I.I.A.: Sch. 10.595, an effective dopamine β-hydroxylase inhibitor and a new hypotensive agent. Pharmacologist 13, 192, abstr. 010 (1971); J. Pharmacol. exp. Ther. 184, 671–677 (1973).PubMedGoogle Scholar
  139. Kralt, T., Asma, W.J., Moed, H.D.: Reserpine analogues III: Alkoxy-β-phenylethylamine derivatives. Rec. Trav. chim Pays-Bas 80, 431–445 (1961).Google Scholar
  140. Kreye, V.A.W., Bechtel, H., Hoebel, M.: Studies on sodium nitroprusside II: Structure-Activity-Relationships (in press).Google Scholar
  141. Kroneberg, G., Oberdorf, A., Hoffmeister, F., Wirth, W.: Zur Pharmakologie von BAY 1470, eines Hemmstoffs adrenergischer und cholinergischer Neurone. Naunyn-Schmiedebergs Arch. Pharmak. exp. Path. 256, 257–280 (1967).Google Scholar
  142. Kroneberg, G., Schlossmann, K., Stoepel, K.: Pharmacology of N-(2-guanidinoethyl)-4-methyl-l, 2, 3, 6-tetrahydropyridine, a new antihypertensive agent. Arzneimittel-Forsch. 17, 199–207 (1967).Google Scholar
  143. Kubikowski, P., Majcherczyk, J., Szymanska, J.: New hydrazinophthalazine derivatives of hypotensive activity. Acta physiol. pol. 16, 289–296 (1965); Chem. Abstr. 64, 5638 (1966).PubMedGoogle Scholar
  144. Kupchan, S.M.: Hypotensive veratrum ester alkaloids. J. pharm. Sci. 50, 273–287 (1961).PubMedGoogle Scholar
  145. Kupchan, S.M., By, A.W.: The chemistry of the veratrum group. In: Manske, R.H.F. (Ed.): The Alkaloids, Vol. X, pp. 193–285. New York-London: Academic Press 1968.Google Scholar
  146. Kupchan, S.M., Flacke, W.E.: Hypotensive veratrum alkaloids. In: Schlittler, E. (Ed.): Antihypertensive Agents, pp. 429–458. New York-London: Academic Press 1967.Google Scholar
  147. Lamb, I. D., White, A. C.: Some amidines and amidoximes with trypanocidal activity. J. chem. Soc. 1939, 1253–1257.Google Scholar
  148. Lape, H.E., Fort, D., Frering, R., Skulan, T.: Antihypertensive activity of a dihydroiso-quinoline carboxamidoxime. Pharmacologist 13, 191 (1971).Google Scholar
  149. Lape, H.E., Hoppe, J.O., Bell, M.R., Wood, D., Selberis, W.H., Arnold, A.: The antihypertensive properties of a series of indole and azaindole amidoximes with particular reference to 7-azaindole-3-acetamidoxime and indole-1-acetamidoxime. Arch. int. Pharmacodyn. 171, 394–414 (1968).Google Scholar
  150. Laverty,R.: A comparison of the behavioural effects of some hypotensive imidazoline derivatives. Europ. J. Pharmacol. 9, 163–169 (1969).Google Scholar
  151. Lee, G.E.: Non-quaternary blockers. In: Schlittler, E. (Ed.): Antihypertensive Agents, pp. 295–329. New York-London: Academic Press 1967.Google Scholar
  152. Lee, G. E., Wragg, W. R., Corne, S. J., Edge, N. D., Reading, H. W.: 1:2:2:6:6-Pentamethylpiperidine, a new hypotensive agent. Nature (Lond.) 181, 1717–1719 (1958).PubMedGoogle Scholar
  153. Leonard, N.J., Hauck, F.P.: Unsaturated amines X: The mercuric acetate route to substituted piperidines, Δ 2-tetrahydropyridines and Δ 2-tetrahydroanabasines. J. Amer. chem. Soc. 79, 5279–5292 (1957).Google Scholar
  154. Leonard, N.J., Nommensen, E.W.: Studies on the mechanism of the von Braun reaction. J. Amer. chem. Soc. 71, 2808–2813 (1949).Google Scholar
  155. Leroy, B. R.: The thiocyanates in solution, the natural physiological solvent of the body. N. Y. med. J. 1909, 802–805.Google Scholar
  156. LeVine, P. B., Gearien, J.E.: Stereospecific synthesis of a reserpine analog. J. Organ. Chem. 26, 4060–4062 (1961).Google Scholar
  157. Libermann, D., Rouaix, A.: Hydrazine derivatives of some heterocyclic compounds. Bull. Soc. chim. Fr. 1959, 1793–1798.Google Scholar
  158. Lindner, E., Kaiser, J.: Tiamenidine (Hoechst 440), a new antihypertensive substance. Arch. int. Pharmacodyn. 211, 305–325 (1974).PubMedGoogle Scholar
  159. Lofgren, N., Erdtman, H.: A new group of compounds acting as local anesthetics. Svensk Kern. Tid. 49, 163–174 (1937).Google Scholar
  160. Lucas, R. A., Kiesel, R. J., Ceglowski, M.J.: Rauwolfia Alkaloids XXXII: Further studies on the synthesis and activity of reserpine analogs. J. Amer. chem. Soc. 82, 493–495 (1960).Google Scholar
  161. Lucas, R.A., Kuehne, M.E., Ceglowski, M.J., Dziemian, R.L., McPhillamy, H.B.: Rauwolfia Alkaloids XXXI: The synthesis and activity of some reserpine analogs. J. Amer. chem. Soc. 81, 1928–1932 (1959).Google Scholar
  162. Mahaffey,L.W.: Toxicity of sodium nitroprusside for guinea pigs. Aust. J. chem. Inst. 9, 93–94 (1942).Google Scholar
  163. Major, R.H.: Possible relationship between guanidine and high blood pressure. Amer. J. med. Sci. 170, 228–232 (1925).Google Scholar
  164. Major, R.H., Stephenson, W.: The effects of methylguanidines. Bull. Johns Hopk. Hosp. 35, 140–141 (1924).Google Scholar
  165. Manchot, W., Düsing, J.: Studies of the similarity of ruthenium to iron: Sodium nitrosopenta cyano ruthenite. Z. anorg. Chem. 212, 109–112 (1933).Google Scholar
  166. Marxer, A., Schier, O.: Quaternary ganglionic blockers. In: Schlittler, E. (Ed.): Antihypertensive Agents, pp. 279–294. New York-London: Academic Press 1967.Google Scholar
  167. Massie, E., Etheridge, C.B., O’Hare, J.P.: Thiocyanate therapy in vascular hypertension. New Engl. J. Med. 219, 736–740 (1938).Google Scholar
  168. Matier, W.L., Comer, W.T., Deitchman, D.: Sulfamoyl azides: Hydrolysis rate and hypotensive activity. J. med. Chem. 15, 538–541 (1972); see also Chem. Abstr. 75, 150.893f (1971).PubMedGoogle Scholar
  169. Maxwell, R.A., Plummer, A.J., Daniel, A.I., Schneider, F., Povalski, H.: Concerning the mechanisms of the cardiovascular actions of hexahydro-1-azepine propionamidoxime. J. Pharmacol. exp. Ther. 124, 127–134 (1958b).PubMedGoogle Scholar
  170. Maxwell, R.A., Mull, R.P., Plummer, A. J.: (2-(Octahydro-l-azocinyl)-ethyl)guanidine sulfate (SU 5864), a new synthetic antihypertensive agent. Experientia (Basel) 15, 267 (1959).PubMedGoogle Scholar
  171. Maxwell, R.A., Ross, S.D., Plummer, A.J.: Pharmacology of hexahydro-1-azepine propionamidoxime (SU 4029). J. Pharmacol. exp. Ther. 123, 128–139 (1958a).PubMedGoogle Scholar
  172. Maxwell, R.A., Schneider, F.L.: Some actions of hexahydro-1-azepine propionamidoxime HCl (SU 4029) in certain autonomic pathways. J. Pharmacol. exp. Ther. 134, 347–355 (1961).PubMedGoogle Scholar
  173. Mazumdar, D.C., Mukherji, K.L.: Rauwolfia in hypertension. J. Indian med. Ass. 19, 362–367 (1950).PubMedGoogle Scholar
  174. McPhillamy, H.B., Huebner, C.F., SchLIttler, E., St. Andre, A.F., Ulshafer, P.R.: Rauwolfia Alkaloids XIX: The constitution of deserpidine and reserpine. J. Amer. chem. Soc. 77, 4335–4343 (1955).Google Scholar
  175. Mull, R.P.: Belgian Patent 611653 (1962). Aminoguanidines. Chem. Abstr. 57, 16414 (1962).Google Scholar
  176. Mull, R.P., Egbert, M.E., Dapero, M.R.: Guanidines with antihypertensive activity I. J. Org. Chem. 25, 1953–1956 (1960).Google Scholar
  177. Mull, R.P., Maxwell, R.A.: Guanethidine and related adrenergic neurone blocking agents. In: Schlittler, E. (Ed.): Antihypertensive Agents, p. 131. New York-London: Academic Press 1967.Google Scholar
  178. Mull, R.P., Maxwell, R.A., Plummer, A.J.: Antihypertensive activity of hexahydro-1-azepine propionamidoxime. Nature (Lond.) 180, 1200–1201 (1957).PubMedGoogle Scholar
  179. Mull, R.P., Mizzoni, R.H., Dapero, M.R., Egbert, M.E.: Guanidines with antihypertensive activity II. J. med. Chem. 5, 944–949 (1962).Google Scholar
  180. Muller, J.M., Schlittler, E., Bein, H.J.: Reserpin, der sedative Wirkstoff aus R. serpentina Benth. Experientia (Basel) 8, 338 (1952).PubMedGoogle Scholar
  181. Muller, G., Allais, A.: Sur quelques analogues synthétiques de la réserpine et de la déserpidine. Naturwissenschaften 47, 82 (1960).Google Scholar
  182. Monro, A.M., Potter, G.W.H., Sewell, M. J.: Adrenergic neurone blocking agents II: Some dioxane-substituted derivatives of guanoxan. J. med. Chem. 10, 880–883 (1967).PubMedGoogle Scholar
  183. Nador, K.: Benzylguanidines. Hungarian Pat. 155717 (Gedeon Richter) Chem. Abstr. 70, 114811r (1969).Google Scholar
  184. Nagatsu, I., Mitsutami, K., Umezawa, H., Matsuzaki, M., Takeuchi, T.: Adrenal tyrosine hydroxylase and dopamine β -hydroxylase in spontaneous hypertensive rats. Nature (Lond.) 230, 381–382 (1971).PubMedGoogle Scholar
  185. Najer, H., Chabrier, P., Giudicelli, R.: Sur quelques amino-2-oxazolines N-substituées douées d’activité vasculaire. Bull. Soc. chim. Fr. 1959, 352–359.Google Scholar
  186. Najer, H., Giudicelli, R.: Sur quelques amino-2-oxazolines N-substituées douées d’activité vasculaire (2° mémoire). Bull. Soc. chim. Fr. 1960, 1650–1652.Google Scholar
  187. Najer, H., Giudicelli, R., Loiseau, J., Menin, J.: Le (triméthoxy-3″-4″-5″-benzoate de β-hydroxyéthyl)-3′-pipéridino-N-ethyl)-3-méthoxy-6-indole. Bull. Soc. chim. Fr. 1963, 2831–2840.Google Scholar
  188. Najer, H., Giudicelli, R., Sette, J.: Une nouvelle synthèse des arylamino-2-imidazolines. Bull. Soc. chim. Fr. 1961, 2114–2126.Google Scholar
  189. Najer, H., Giudicelli, R., Sette, J.: Guanidines with antihypertensive activity IV: N-(β-guanidinoethyl)azaspiroalkanes. Bull. Soc. chim. Fr. 1964, 2572–2581.Google Scholar
  190. Najer, H., Giudicelli, R., Sette, J., Menin, J.: Guanidines with antihypertensive activity V: N-(β-guanidinoethyl)azaspiroalkanes. Bull. Soc. chim. Fr. 1965, 204–208.Google Scholar
  191. Nakamura, T., Yasuda, H., Obayashi, A., Tanabe, O., Matsumura, S., Ueda, F., Ohata, K.: Antihypertensive and fungal dopamine β-hydroxylase inhibitor. J. Antibiot. (Tokyo) 28, 477 (1975). Chem. Abstr. 83, 75.176J (1975).Google Scholar
  192. Nogradi, T.: Untersuchungen über Rauwolfia-Alkaloid-Modelle I: Tryptamin- und Graminderivate. Mh. Chem. 88, 768–777 (1957a).Google Scholar
  193. Nogradi, T.: Untersuchung über Rauwolfia-Alkaloid-Modelle II: 2-substituierte Indole, Tetrahydrocarbolin- und Hexahydroyohimbanderivate. Mh. Chem. 88, 1087–1094 (1957b).Google Scholar
  194. Norton, S., Phillips, A.P.: A new type of autonomic blocking agent. Nature (Lond.) 172, 867 (1953).Google Scholar
  195. Ozawa, H., Gomi, Y., Otsuki, L: Pharmacological studies of guanethidine dervatives III: Yakugaku Zasshi 85, 112–119 (1965); Chem. Abstr. 62, 15314 (1965).Google Scholar
  196. Ozawa, H., Sato,S.: The adrenergic neurone blocking action of 2-(methylphenylamino)ethyl-guanidine sulfate: Chem. Pharm. Bull. (Tokyo) 14, 1291–1297 (1966); 15, 840–844 (1967).PubMedGoogle Scholar
  197. Paco, G. Di, Tauro, C.S.: On some new esters and amides of 3, 4, 5-trimethoxy benzoic acid with potential reserpine activity. Farmaco, Ed. sci. 13, 64–74 (1958).Google Scholar
  198. Page, I.H.: The nature of treatment of hypertension. Trans. Amer. ther. Soc. 48, 56–70 (1947).Google Scholar
  199. Page, I.H.: Humoral and vasomotor controls of blood vessels. Bull. N. Y. Acad. Med. 28, 131–144 (1952).PubMedGoogle Scholar
  200. Page, I. H.: Drug treatment in hypertension. A public lecture given at the Symposium on antihypertensive therapy, principles and practice (Gross, F. Ed.), pp. 602–614. Berlin-Heidelberg-New York: Springer 1966.Google Scholar
  201. Page, I.H., Corcoran, A., Dustan, P.H., Koppany, T.: Cardiovascular actions of sodium nitroprusside in animals and hypertensive patients. Circulation 11, 188–198 (1955).PubMedGoogle Scholar
  202. Parsons, D.G., Turner, A.F., Murray, B.G.: Substituted 1-aminophthalazines. Chem. Abstr. 70, 57872k (1969); see also (Vantorex Ltd.) New substituted phthalazines. Chem. Abstr. 68, 49632a (1968).Google Scholar
  203. Paton, W. D. M., Zaimis, E. J.: The pharmacological actions of the polymethylene bistrimethylammonium salts. Nature (Lond.) 161, 718–719 (1948); Brit. J. Pharmacol. 4, 381–400 (1949).Google Scholar
  204. Pauli, W.: Zur Kenntnis der Rhodantherapie. Zbl. ges. Ther. 22, 19 (1904).Google Scholar
  205. Peterfalvi, M., Jequier, R.: La 10-méthoxy déserpidine: étude pharmacologique. Arch. int. Pharmacodyn. 124, 237–254 (1960).PubMedGoogle Scholar
  206. Pezzangaro, F.: Treatment of arterial hypertension by intravenous injection of octyl alcohol. C. R. Soc. Biol. (Paris) 119, 1331–1333 (1935).Google Scholar
  207. Pham-Huu-Chanh, Lecointe, P., Donnat, L.: Pharmacology of barium nitrosyl pentacyano ferrate. Arzneimittel-Forsch. 19, 1836–1842 (1969).Google Scholar
  208. Plattner, P.A., Keller, W., Boller, A.: Welkstoffe und Antibiotika. Konstitution und Synthese der Fusarinsäure. Synthese von 5-Äthyl- und 5-n-Hexylpyridin-2-carbonsäure. Helv. chim. Acta 37, 1379–1392 (1954).Google Scholar
  209. Plummer, A. J., Schneider, J. A., Barrett, W. E.: A series of tris (dialkylaminoalkyl) amines with ganglionic blocking activity. Arch. int. Pharmacodyn. 97, 1–12 (1954).PubMedGoogle Scholar
  210. Popelak, A., Lettenbauer, G.: Über die Verätherung der Yohimbanalkaloide mit Diazomethan. Arch. Pharm. 295, 427–430 (1962).PubMedGoogle Scholar
  211. Protiva, M., Jilek, J.O., Hach, V., Adlerova, E., Michajlyszyn, V.: Einfache Reserpin-modelle mit dem Cyclohexanring E. Coll. Czech. Chem. Commun. 24, 83–92 (1959a).Google Scholar
  212. Protiva, M., Vejdelek, Z. J., Jilek, J. O., Macek, K.: Einige weitere Derivate des Tryptamins und 1, 2, 3, 4-Tetrahydronorharmans. Coll. Czech. Chem. Commun. 24, 3978–3987 (1959b).Google Scholar
  213. Pruss, T.P., Hidalgo, J.: Cardiovascular profile of the antihypertensive agent guanadrel. Proc. Soc. exp. Ther. 139, 600–603 (1972).Google Scholar
  214. Raffa, L., Monzani, A., Di Bella, M.: 1, 2, 4-Benzothiadiazine derivatives XVIII: The chlorination of 3-oxodihydrobenzo-l, 2-thiadiazine-l,l-dioxide. Farmaco, Ed. sci. 17, 234–243 (1962); Chem. Abstr. 58, 3435 (1963).Google Scholar
  215. Racine, M.: A propos des traitements récents de l’hypertension artérielle. J. Prat. (Paris) 49, 753–756 (1935).Google Scholar
  216. Rieppel, F.W.: Leonhard Rauwolf. Ein Beitrag zu seiner Biographie. Dtsch. med. Wschr. 80, 653–655 (1955).PubMedGoogle Scholar
  217. Rieppel, F.W.: Zur Frühgeschichte der Rauwolfia. Sudhoffs Arch. Gesch. Med. 40, 231–239 (1956).Google Scholar
  218. Robertson, J.E.: Biguanides French Patent 1.320.255 (1963); Chem. Abstr. 59, 10.010 (1963).Google Scholar
  219. Robison, M.M., Lucas, R.A., McPhillamy, H.B., Barrett, W., Plummer, A.J.: Rauwolfia Alkaloids XXXV: Potent, fast acting sedatives from methylreserpate. Experientia (Basel) 17, 14 (1961a).Google Scholar
  220. Robison, M.M., Lucas, R.A., McPhillamy, H.B., Dziemian, R.L., Hsu, I., Kiesel, R.J.: Rauwolfia Alkaloids XXXVI: Non-hypotensive sedatives derived from methylreserpate. J. Amer. chem. Soc. 83, 2694–2700 (1965b).Google Scholar
  221. Rodriguez, R., Hong, E., Vidrio, H., Pardo, E.G.: Pharmacology of a group of phenyl-piperazine tetrazole derivatives with adrenergic blocking actions. J. Pharmacol. exp. Ther. 148, 54–65 (1965).PubMedGoogle Scholar
  222. Roth, F.E., Schurr, J., Moutis, E., Govier, W.M.: Comparative hypotensive effect and toxicity of sodium azide and selected organic azides. Arch. int. Pharmacodyn. 108, 473–480 (1956).PubMedGoogle Scholar
  223. Rubin, A.A., Roth, F.E., Winbury, M.M.: A non-diuretic benzothiadiazine with antihypertensive properties. Nature (Lond.) 192, 176–177 (1961).Google Scholar
  224. Rubin, A.A., Roth, F.E., Winbury, M.M., Topliss, J.G., Sherlock, M.H., Sperber, N., Black, J.: A new class of antihypertensive agents. Science 133, 2067 (1961).PubMedGoogle Scholar
  225. Russel, W.O., Stahl, W.C.: Fatal poisoning from potassium rhodanide treatment of hypertension. J. Amer. med. Ass. 119, 1177–1181 (1942).Google Scholar
  226. Sah, H.J., Sah, P.P.T., Peoples, S.A.: The new antihypertensive agent guanethidine: a review. Discovery and development, chemical structure, physical properties, and pharmacological actions. Arzneimittel-Forsch. 16, 53–58 (1966).Google Scholar
  227. Sandoz: Belg. Pat. 737.553 (U.S. priority 8/16 and 26/1968).Google Scholar
  228. Saunders, J.P., Himwich, W. A.: Properties of the transsulfurase responsible for conversion of cyanide to thiocyanate. Amer. J. Physiol. 163, 404–409 (1950).PubMedGoogle Scholar
  229. Schier, O., Marxer, A.: Antihypertensive agents 1962–1968. In: Jucker, E. (Ed.): Progress in Drug Research, Vol. 13, pp. 101–135/Basel-Stuttgart: Birkhäuser 1969.Google Scholar
  230. Schlittler, E.: Rauwolfia alkaloids with special reference to the chemistry of reserpine. In: Manske, R.H.F. (Ed.): The Alkaloids, Vol. 8, pp. 287–334. New York: Academic Press 1965.Google Scholar
  231. Schlittler, E., Druey, J., Marxer, A.: Antihypertensive agents. In: Jucker, E. (Ed.): Progress in Drug Research, Vol. 4, pp. 295–351. Basel-Stuttgart: Birkhäuser 1962.Google Scholar
  232. Schoepke, H.G., Brondyk, H.D., Wiemeler, L.H., Schmidt, J.L.: Cardiovascular pharmacology of tertiary octylguanidine (B.P. 1184). Arch. int. Pharmacodyn. 153, 185–204 (1965).Google Scholar
  233. Schuemann, H. J., Werner, U.: Hemmung der Hormonfreisetzung aus dem Nebennierenmark durch BAY 6781, eine antihypertensive Substanz. Naunyn-Schmiedebergs Arch. Pharmak. 268, 71–82 (1971).Google Scholar
  234. Scriabine, A., Booher, K.D., Pereira, J.N., McShane, W.K., Constantine, J.W., Koch, R.C., Miknius, S.: Pharmacological studies with guanisoquin. J. Pharmacol. exp. Ther. 147, 277–287 (1965).PubMedGoogle Scholar
  235. Scriabine, A., Booher, K.D., Pereira, J.N., McShane, W.K., Koch, R.C.: Some pharmacological actions of N,N′-dimethyl-l, 2, 3, 4-tetrahydroisoquinoline-2-carboxamidine HCl (P-4746). Arch. int. Pharmacodyn. 164, 435–443 (1966).Google Scholar
  236. Semonsky, M., Zikan, V., Votova, Z., Podvalova, L, Ponec, K.: N(D-6-Methyl-8-isoergolenyl)-N, N-diethylurea acid maleate (LYSENYL-Spofa, a new antiserotonine drug). Čs. Farm. 17, 296–305 (1968). C. A. 70, 1976e (1969).Google Scholar
  237. Sen, G., Bose, K.C.: Rauwolfia serpentina: A new Indian drug for insanity and high blood pressure. Indian med. World 2, 194–201 (1931).Google Scholar
  238. Sherman, G. P.: Bradycardia effects of the antihypertensive agent 2, 6-dichlorobenzylidene aminoguanidine acetate (WY 8678) in the dog. Pharmacologist 13, 192 (abstr. 005) (1971).Google Scholar
  239. Short,J.H., Darby, T.D.: Sympathetic nervous system blocking agents III: Derivatives of benzylguanidines. J. med. Chem. 10, 833–840 (1967).PubMedGoogle Scholar
  240. Short, J.H., Ours, C.W., Ranus, W.J.: Sympathetic nervous system blocking agents V: Derivatives of isobutyl-, tert. butyl-, and neopentyl-guanidine. J. med. Chem. 11, 1129–1135 (1968).PubMedGoogle Scholar
  241. Siddiqui, S.: A note on the alkaloids of R. serpentina Benth. J. Indian chem. Soc. 16, 421–422 (1939).Google Scholar
  242. Siddiqui, S., Siddiqui, R.H.: Chemical examination of the roots of R. serpentina Benth. J. Indian. chem. Soc. 8, 667–680 (1931).Google Scholar
  243. Siddiqui, S., Siddiqui, R. H.: Alkaloids of Rauwolfia serpentina Benth. Part. I. J. Indian chem. Soc. 9, 539–544 (1932).Google Scholar
  244. Siddiqui, S., Siddiqui, R. H.: The alkaloids of R. serpentina Benth. Part II: Studies in the ajmaline series. J. Indian chem. Soc. 12, 37–47 (1935).Google Scholar
  245. Sivach, T.A., Kapitonenko, T. A.: Hypotensive properties of 3-azidocyclohexanone semicarbazone. Chem. Abstr. 83, 71780d (1975).Google Scholar
  246. Sonn, A.: Imidazolines. U.S. Pat. 2.161.938 (Chem. Abstr. 33, 7316 (1939).Google Scholar
  247. Spivakova, R.P.: Pharmacological properties of a number of sympatholytics, derivatives of guanidine. Farmakol. i Toksikol 34, 650–653 (1971). [Chem. Abstr. 76, 108017u (1972)].Google Scholar
  248. Spinks, A., Young, E. H. P.: Polyalkylpiperidines: A new series of ganglionic blocking agents. Nature (Lond.) 181, 1397–1398 (1958).Google Scholar
  249. Stieglitz, E. J.: Bismuth subnitrate in the therapy of hypertension. J. Pharmacol. exp. Ther. 32, 23–35 (1928).Google Scholar
  250. Stieglitz, E. J.: Therapeutic results with bismuth subnitrate in hypertensive arterial disease. J. Pharmacol. exp. Ther. 46, 343–356 (1932).Google Scholar
  251. Stoll, A., Hofmann, A.: Die Alkaloide der Ergotoxingruppe: Ergocristin, Ergokryptin und Ergocornin. Helv. chim. Acta 26, 1570–1601 (1943).Google Scholar
  252. Stoll, A., Hofmann, A.: The ergot alkaloids. In: Manske, R.H.F. (Ed.). The Alkaloids, Chemistry and Physiology, Vol. VIII, pp. 725–783. New York-London: Academic Press 1965.Google Scholar
  253. Stoll, A., Hofmann, A.: The chemistry of the ergot alkaloids. In: Pelletier, S.W. (Ed.): Chemistry of the Alkaloids, pp. 267–300. New York: Van Nostrand Reinhold 1970.Google Scholar
  254. Suda, H., Takeuchi, T., Nagatsu, T., Matsuzaki, U., Matsumoto, L, Umezawa, H.: Inhibition of dopamine β-hydroxylase by 5-alkylpicolinic acids and their hypotensive effects. Chem. pharm. Bull. 17, 2377–2380 (1969).PubMedGoogle Scholar
  255. Symchowicz, S., Staub, M.: Disposition of Sch. 10595 in animals and man. J. Pharmacol. exp. Ther. 191, 324–330 (1974).PubMedGoogle Scholar
  256. Tamari, K., Kaji, J.: The mechanism of the growth inhibiting action of fusarinic acid on plants: Chem. Abstr. 48, 8330 (1954).Google Scholar
  257. Terasawa, F., Kameyama, M.: Clinical trial of a new hypotensive agent, fusaric acid (5-butylpicolinic acid). Chem. Abstr. 79, 27527 (1973).Google Scholar
  258. Topliss, J.G., Konzelman, L.M., Shapiro, E.P., Sperber, N., Roth, F.E.: Antihypertensive agents II: 3 Substituted 2H 1, 2, 4 benzothiadiazine-l, l dioxides. J. med. Chem.7, 269–273 (1964).PubMedGoogle Scholar
  259. Topliss, J.G., Sherlock, M.H., Reimann, H., Konzelman, L.M., Shapiro, E.P., Pettersen, B.W., Schneider, H., Sperber, N.: Antihypertensive agents I: Non diuretic 2H-1, 2, 4-benzothiadiazine-l,l-dioxides. J. med. Chem. 6, 122–127 (1963).PubMedGoogle Scholar
  260. Topliss, J. G., Yudis, M.D.: Correlation of antihypertensive activity with structure in a series of 2H-1, 2, 4 benzothiadiazine-1,1-dioxides using the substituent constant approach. J. med. Chem. 15, 394–400, 400–403 (1972).PubMedGoogle Scholar
  261. Trcka, V., Dlabac, A., Vanecek, M.: Mediodespidine, hypotensive reserpoid without sedative effect I: Comparison of sedative and hypotensive activity in monkeys. Life Sci. 4, 2257–2261 (1956a).Google Scholar
  262. Trcka, V., Carlsson, A.: Part II: Effect on monoamine levels in mouse organs. Life Sci. 4, 2263–2267 (1965b).PubMedGoogle Scholar
  263. Turner, F.A., Gearien, J.E.: Synthesis of reserpine analogs. J. org. Chem. 24, 1952–1955 (1959).Google Scholar
  264. Ueno, K., Ishikawa, F., Miyazaki, S.: Pyrido (3–4d) pyridazine derivatives. Chem. Abstr. 75, 140874–140876 (1971).Google Scholar
  265. Ueno, K., Miyazaki, S., Akashi, A.: Hypotensive l-(alkylidenehydrazino)-phthalazines. Chem. Abstr. 77, 5504s (1972).Google Scholar
  266. Umezawa, H., Takeuchi, T., Miyano, K., Hamano, H., Tanaka, W.: Antihypertensive 5(ω-haloalkyl)picolinic acids. Ger. Offen. 2305758 (Chem. Abstr. 79, 115.444w (1973).Google Scholar
  267. Urech, E., Marxer, A., Miescher, K.: 2-Aminoalkyl-imidazoline. Helv. chim. Acta 33, 1386–1407 (1950).Google Scholar
  268. Vakil, R.J.: A clinical trial of R. serpentina in essential hypertension. Brit. Heart J. 11, 350–355 (1949).PubMedGoogle Scholar
  269. Vazakas, A. J., Doluisio, J.T.: Synthesis and pharmacology of some basic esters of 3, 4, 5-trimethoxybenzoic acid. J. pharm. Sci. 53, 165–169 (1964).PubMedGoogle Scholar
  270. Vedernikov, Y.P.: Effects of Redergam on vascular responses to sciatic nerve stimuli. (Russ.). Chem. Abstr. 61, 12505 (1964).Google Scholar
  271. Vedernikov, Y.P.: Pharmacology of Redergam and assays of its analgesic activity in animal and clinical tests. Farmakol. i Toksikol. 26, 431–434 (1963) (Russ.). Chem. Abstr. 60, 2234 (1964).Google Scholar
  272. Vejdelek, Z.D., Trcka, V., Protiva, M.: Chemistry of 1, 2, 3, 4-Tetrahydronorharman-l-carboxylic acid and derivatives. J. Med. Pharm. Chem. 3, 427–440 (1961).PubMedGoogle Scholar
  273. Velasco, M., Gilbert, C.A., Rutledge, C.O., McNay, J.L.: Bupicomide: Clin. Pharmacol. Ther. 18, 145–153 (1975).Google Scholar
  274. Velasco, M., McNay, J.L.: Clin. Pharmacol. Ther. 15, 222 (1974).Google Scholar
  275. Velluz, L.: Réserpines de synthèse. Ann. pharm. franç. 17, 15–25 (1959); Prod, pharm. 14, 607–609 (1959).Google Scholar
  276. Velluz, L., Muller, G., Allais, A.: 6-Alcoyl réserpines. C. R. Acad. Sci. (Paris) 247, 1746–1748 (1958b).Google Scholar
  277. Velluz, L., Mullee, G., Allais, A.: Deserpidine derivatives. French pat. 1.180.514 (1959); Chem. Abstr. 55, 9450 (1961).Google Scholar
  278. Velluz, L., Peterfalvi, M., Jequier, R.: Un clivage des effects réserpiques. C. R. Acad. Sci. (Paris) 247, 1905–1907 (1958a).Google Scholar
  279. Votava, Z., Podvalova,L., Vojtechovsky, M.: Unterschiede in der pharmakologischen Wirkung von halluzinogenen und nicht halluzinogenen Lysergsäurederivaten (LSD-25, Deseryl, Lysenyl und Mesenyl). Arzneimittel-Forsch. 16, 220–222 (1966).Google Scholar
  280. Warawa, E.J.: Synthesis of 3-alkyl-2, 6-dicyanopyridines by a unique rearrangement. Preparation of fusaric acid analogs. J. org. Chem. 40, 2092–2095 (1975).Google Scholar
  281. Wenner, W.: 1, 2, 3, 4-Tetrahydroisoquinoline derivatives with antihypertensive properties. J. med. Chem. 8, 125–126 (1965).PubMedGoogle Scholar
  282. Werle, E., Fried, R.: Zur Kenntnis der biologischen Wirkung organischer Azide. Biochem. Z. 322, 507–512 (1952).Google Scholar
  283. Werle, E., Fried, R.: Über das Azid-entgiftende Ferment tierischer Gewebe. Biochem. Z. 321, 500–507 (1951).Google Scholar
  284. Werle, E., Fried, R.: Monoamidoxydase und Azidabbau durch tierische Gewebe. Biochem. Z. 323, 14–20 (1952).Google Scholar
  285. Werle, E., Mennicken, G.: Über die Inaktivierung von Tryptamin und Tyramin durch tierische Gewebe. Biochem. Z. 296, 99–104 (1938).Google Scholar
  286. Werle, E., Stücker, F.: Zur Pharmakologie der Azide. Arzneimittel-Forsch. 8, 28–31 (1958).Google Scholar
  287. Werner, L.H., Barrett, W.E.: Adrenergic blocking agents. In: Schlittler, E. (Ed.): Antihypertensive Agents, pp. 331–392. New York-London: Academic Press 1967.Google Scholar
  288. Westphal, K.: Über die Rhodantherapie des genuinen arteriellen Hochdrucks. Münch. med. Wschr. 73, 1187 (1926).Google Scholar
  289. Westphal,K., Blum, R.: Die Rhodantherapie des genuinen arteriellen Hochdrucks und ihre Bedeutung. Dtsch. Arch. klin. Med. 152, 331–353 (1926).Google Scholar
  290. Wilson, J., Vesey, C.J., Cole, P.V.: Nitroprusside revisited. Brit. med. J. 1971 IV, 116.Google Scholar
  291. Wollweber, H., Wilms, H., Hiltmann, R., Stoepel, K., Kroneberg, G.: Guanidinoalkyl-azacycloalkanes: Chemical structure and antihypertensive activity. Arzneimittel-Forsch. 21, 2089–2100 (1971).Google Scholar
  292. Woodward, R.B., Bader, F.E., Bickel, H., Frey, A.J., Kierstead, R. W.: The total synthesis of reserpine. J. Amer. chem. Soc. 78, 2023–2025, 2657 (1956); Tetrahedron 2, 1–57 (1958).Google Scholar
  293. Wylie, D.W., Archer, S.: Structure-activity relationships of l-[(3-indolyl)-alkyl]-4-aryl piperazines, a new series of tranquilizers. J. med. Pharm. Chem. 5, 932–943 (1962).Google Scholar
  294. Yabuta, T., Kambe, K., Hayashi, T.: Fusarinic acid, a new product of the bakanae fungus. Chem. Abstr. 29, 1132 (1935).Google Scholar
  295. Zikan, V., Semonsky, M.: Mutterkornalkaloide, Mitt. 31: Ein Beitrag zur Herstellung von N(D-6-Methyl-8-isoergolenyl)N, N′-diäthylharnstoff. Pharmazie 23, 147–148 (1968).Google Scholar
  296. Zins, G.R.: The in vivo production of a potent, long-acting hypotensive metabolite from diallylmelamine. J. Pharmacol. exp. Ther. 150, 109–117 (1965).PubMedGoogle Scholar
  297. Zins, G.R., Emmert, D.E., Walk, R.A.: Hypotensive metabolite production and sequential metabolism of N, N-diallylmelamine in rats, dogs, and man. J. Pharmacol. exp. Ther. 159, 194–205 (1968).PubMedGoogle Scholar
  298. Zwieten, P. A. van: A new antihypertensive compound, 44–549. Pharmacology 13, 352 (1975).PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1977

Authors and Affiliations

  • E. Schlittler

There are no affiliations available

Personalised recommendations